Meet ISPOR Board Of Directors
Joanna Lis
DIRECTOR (2016-2018): Joanna Lis, MSc, MBA, PhD

Joanna Lis, MSc, MBA, PhD is an assistant professor in the Department of Pharmacoeconomics at Faculty of Pharmacy at the Medical University of Warsaw (WUM) and a Director of Market Access in Sanofi Poland. Prior to joining the Medical University of Warsaw and Sanofi, Joanna held various leadership positions in the HE area at Johnson & Johnson and Eli Lilly.

Dr. Lis is a deputy Editor-in-Chief of the Journal of Health Policy and Outcomes Research ( and a member of the experts' team of the Polish HTA Agency working on HTA guidelines updates (2016) for Poland. She is the President of the ISPOR Poland Chapter as well as a member of the ISPOR Central and Eastern Europe (CEE) Network.

Dr. Lis holds a PhD in biostatistics and computer modelling in medicine, MSc in mathematics and physics from the Jagiellonian University in Cracow and an executive MBA from Kozminski University of Business and Management in Warsaw.

She has published over 70 articles. She is a co-author of various books and reports: “Pricing” – advancing contracting, “Health Insurance Policy and Benefit Baskets” and “Indirect Costs in HTA: methods and recommendations.”

Dr. Lis holds a PhD in biostatistics and computer modelling in medicine, MSc in mathematics and physics from the Jagiellonian University in Cracow and an executive MBA from Kozminski University of Business and Management in Warsaw.

As an active member of ISPOR, she has been heavily involved in the ISPOR Patient Registry Special Interest Group: (ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms) and ISPOR Task Force for Transferability of Economic Evaluations across Jurisdictions. Dr. Lis has served as the Co-Chair of the Issue Panel Review Committee at ISPOR 13th Annual European Congress in Prague. Dr. Lis also co-organized the 5th Polish-Russian and Polish-Kazakh-Russian Forums on Pharmacoeconomics. She is also the co-editor of the Polish translation of ISPOR books: “Health Care Cost, Quality and Outcomes: ISPOR Book of Terms” and “Therapeutic & Diagnostic Device Outcomes Research.”

ISPOR Vision Statement by Joanna Lis, MSc, MBA, PhD

Today ISPOR is widely regarded as the leading scientific and educational organization for health economics and outcomes research and its use in decision making to improve health. Tomorrow however, ISPOR must face new challenges and trends in health care worldwide. For example, digitization of medicine, the use of wearables and health for tracking outcomes in real time are linked with the explosion of new data. “Big Data” can improve health technology assessment but it requires new models and provides new tools to measure medical technology value from discovery to value pricing.

We have to be ready also for personalization in medicine. Individual patients’ responses to therapies will require new solutions and their translation into medical practice. The P4 medical approach will help to identify the right drug for the right patient at the right time, avoiding the prescription of costly and ineffective drugs and preventing potentially harmful side-effects, but it will require new ways for scientists to engage with each other, new relations between patients, scientists, and industry and, finally, it will require new strategic partnerships among all stakeholders in the personalized medicine field. ISPOR’s task will be able to support this process.

Moreover informed and demanding patients are now more engaged in their own health care. Therefore, ISPOR has to strengthen its cooperation with different patients groups, organizations and individuals and continue to work on the development and the implementation of advanced evidence-based health care decision-making tools (MDCA).

These global trends pose both challenges and opportunities for ISPOR. As a member of the ISPOR Board, I will work towards overcoming these challenges. I will encourage the development (evidence generation) of new methods and tools, the promotion of scientific standards and fostering better understanding of how and why decisions are made (education and dissemination). I will further collaborate with others to assure that these new solutions are used appropriately throughout different health care systems (communication).

By promoting global development of methods to assess drug/device value in this new health care environment, I will encourage ISPOR to support the development and the application of methods that reflect individual markets' specific needs and realities. ISPOR should continue the development of local Chapters and Task Forces, improve access to information and encourage support growth of Regional Networks, as regionalization is an important step toward globalization.

The new research, tailored education, and innovative communication are necessary to achieve ISPOR’s Vision 2020.

Thank you for your consideration.



ISPOR Board of Directors